Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma

Modern Pathology

Volumn 25, Issue 5, 2012, Pages 758-766

  Chung, Yeon Tae ^a   Matkowskyj, Kristina A ^a   Li, Haonan ^a   Bai, Han ^a   Zhang, Wanying ^a   Tsao, Ming Sound ^a   Liao, Jie ^b   Yang, Guang Yu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

AKR1B10; immunohistochemistry; pancreatic adenocarcinoma; prenylation; smoking

Indexed keywords

K RAS PROTEIN; OXIDOREDUCTASE; PROTEIN AKR1B10; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 84862808747     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.191     Document Type: Article

References (49)

1. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998;273:11429-11435. (Pubitemid 28272034)
2. Hyndman DJ, Flynn TG. Sequence and expression levels in human tissues of a new member of the aldoketo reductase family. Biochem Biophys Acta 1998;1399:198-202. (Pubitemid 28410465)
3. Liu Z, Zhong L, Krishack PA, et al. Structure and promoter characterization of aldo-keto reductase family 1. B10 gene. Gene 2009;437:39-44.
4. Penning TM, Drury JE. Human aldo-keto reductases: functions, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007;464: 241-250. (Pubitemid 47214569)
5. Fukumoto S, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11: 1776-1785. (Pubitemid 40471839)
6. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009;69:3681-3688.
7. Gallego O, Ruiz F, Ardèvol A, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 2007;104:20764-20769.
8. Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008;283:3418-3423.
9. Quinn AM, Harvey RG, Penning TM. Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem Res Toxicol 2008;21:2207-2215.
10. Endo S, Matsunaga T, Mamiya H, et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys 2009;487:1-9.
11. Martin HJ, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009;178:145-150.
12. Casey P. Lipid modifications of G proteins. Curr Opin Cell Biol 1994;6:219-225. (Pubitemid 24109779)
13. Marshall CJ. Protein prenylation: a mediator of proteinprotein interactions. Science 1993;259:1865-1866. (Pubitemid 23124458)
14. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-269. (Pubitemid 26250610)
15. Sebti SM, Hamilton AD, (eds). Farnesyltransferase Inhibitors in Cancer Therapy. No. 8. Humana Press: Totowa, 2001;296.
16. Gao J, Liao J, Yang G-Y. CAAX-box protein, prenylation process and carcinogenesis. Am J Transl Res 2009;1: 312-325.
17. Lowy DR, Willumsen BM. Function and regulation of Ras. Annu Rev Biochem 1993;62:851-891. (Pubitemid 23237890)
18. Ruiz FX, Gallego O, Ardevol A. et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Bio Interact 2009;178:171-177.
19. Crosas B, Hyndman DJ, Gallego O, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003;373: 973-979. (Pubitemid 36981109)
20. Gallego O, Belyaeva OV, Porté S, et al. Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/ reductases and aldo-keto reductases with retinoids. Biochem J 2006; 399:101-109. (Pubitemid 44505411)
21. Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009;284:26742-26748.
22. Balendiran GK, Martin HJ, El-Hawary Y, et al. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Bio Interact 2009;178:134-137.
23. Tzankov S, Wong MJ, Shi K, et al. Functional divergence between co-chaperones of Hsc70. J Biol Chem 2008;283:27100-27109.
24. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004;64:5659-5663. (Pubitemid 39095562)
25. Wang X-Q, Li H, Van Putten V, et al. Oncogenic K-ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell 2009;20:791-800.
26. Li JN, Li X, Qian JM, et al. Effects of K-ras gene mutation on colon cancer cell line Caco-2 metastasis by regulating E-cadherin/beta-catenin/p120 protein complex formation and RhoA protein activity. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010;32:46-50.
27. Rachagani S, Senapati S, Chakraborty S, et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 2011;104:1038-1048.
28. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin 2011;61:212-236.
29. Hidalgo PM, Ferrero HE, Castillo FMJ, et al. Epidemiology and diagnosis of the pancreatic cancer. Rev Esp Enferm Dig 2004;96:714-722.
30. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111. (Pubitemid 39062369)
31. Chang KJ, Parasher G, Christie C, et al. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 2005;103:349-357. (Pubitemid 40129295)
32. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004;34:238-244. (Pubitemid 43102883)
33. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437. (Pubitemid 23143844)
34. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002;51:849-852. (Pubitemid 35408607)
35. Penning TM. AKR1B10: A new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 2005;11:1687-1690. (Pubitemid 40476161)
36. Wang R, Wang G, Ricard MJ, et al. Smoking-induced up-regulation of AKR1B10 expression in the airway epithelium of healthy individuals. Chest 2010;138: 1402-1410.
37. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004;101:6062-6067. (Pubitemid 38520528)
38. Kim B, Lee HJ, Choi HY, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007;67:7431-7438. (Pubitemid 47206573)
39. Endo S, Matsunaga T, Ohta C, et al. Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. Chem Biol Interact; published online 25 December 2010 [E-pub ahead of print].
40. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-554. (Pubitemid 24058210)
41. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
42. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689. (Pubitemid 19213607)
43. Fernandez C, Chentaille B, Tasei AM, et al. From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. Gastroenterol Clin Biol 2005;29:465-468. (Pubitemid 40646495)
44. Löhr M, Klöppel G, Maisonneuve P, et al. Frequency of Kras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23. (Pubitemid 40209467)
45. Dutta SK, Bustin MP, Russell RM, et al. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. Ann Intern Med 1982;97:549-552. (Pubitemid 12000700)
46. Nakamura TTK, Imamura K, Tando Y, et al. Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Acta Gastroenterol Belg 1996;59:10-14. (Pubitemid 26173281)
47. Nakamura TTT. Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Pancreas 1997;14:323-333.
48. Dutta SK, Bustin MP, Russell RM, et al. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. Ann Intern Med 1982;97:549-552. (Pubitemid 12000700)
49. Alberts DS, Garcia DJ. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. J Nutr 1995;125(3 Suppl):692S-697S.